Safety and Feasibility of Repeated Intrathecal Allogeneic Bone Marrow-Derived Mesenchymal Stromal Cells in Patients with Neurological Diseases

Table 2

Adverse events for intrathecal injection of allogeneic MSCs.

Adverse effects (no. of patients)	AD	ADEM	ES	HSP	ICH	IS	ML	MND	MS	MSA	SCA	SCI	TBI	TP	Total
Headache	0	0	0	1	0	0	0	2	0	0	0	0	0	0	3
Dizziness	0	0	0	0	0	1	1	0	0	0	0	0	0	0	2
Fever	0	2	0	0	0	1	0	0	0	0	1	1	0	0	5
Nausea	0	0	0	0	0	0	0	2	0	0	0	0	0	0	2
Pain at puncture site	0	0	0	0	0	3	0	1	0	1	1	0	0	0	6
Neck pain	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1

Abbreviations: AD, Alzheimer’s disease; ADEM, acute disseminated encephalomyelitis; ES, encephalopathy syndrome; HSP, hereditary spastic paraplegia; ICH, intracerebral haemorrhage; IS, ischaemia stroke; ML, myelitis; MND, motor neuron disease; MS, multiple sclerosis; MSA, multiple system atrophy; SCA, spinocerebellar ataxia; SCI, spinal cord injury; TBI, traumatic brain injury; TP, thermoplegia.